BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear. doi.org/10.1172/JCI200442 Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG. The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy. #BladderCancer #BCGtherapy

Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer: doi.org/10.1172/JCI200442

Exciting opportunity! The AUA is seeking a highly-qualified member to fill the position of AUA’s next Editor of The Journal of Urology®. 🚨 Apply by June 29, 2026 for consideration! Learn more here ➡️ bit.ly/4aQjJfH #TheVoiceofUrology

Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI

Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jM…

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology

MR3🌑 ErdaiDRS. BCG unresponsive. (It’s like SR5-> FGFR3)

MR2🌑 FGFR3 agnostic. Ablative (noTURBT) for IR. results coming.

TIP#5 Tyra-300 IR NMIBC. oral FGFR3

TIP#3 Enlighted Ph3. VTP for UTUC. very reasonable response for LG UTUC

TIP#2. So excited for ARCIS. @SWOG. First RCT of BCG unresponsive NMIBC. CRETO-gem vs gem-doce. @MarkTysonMD @cgoncology

TIP#1 Bel-sar. Novel neoajuvant injection mechanism. #AUA2026

Come join us for a deep dive into Clinical Trials in Progress - Hall B, The Square, Learning Lab ... at 9 am ET TODAY #AUA26

The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery. This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives). It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense. ‘It is the first companion diagnostic approval in the field of blood-based MRD.’ natera.com/company/news/sign…

Very reasonable responses - Legend on its way

Congratulations to the newly awarded 2026 National Residency Abstract Olympics winners! 🏆 @CleClinicUro @NM_Urology @WCMUrology #AUA26